| [ Summary ] |
Dialysis hypotension is one of the most common cardiovascular complications for hemodialysis patients. Treatment of dialysis hypotension is not well established at this time, because many factors effect pathophysiology in relation to dialysis hypotension. Dialysis hypotension leads to increased morbidity and mortality in the same way as hypertension. Various pharmacologic agents used for dialysis hypotension, and several effective drugs have been reported on, such as amezinium metilsulfate, droxidopa. The goal of pharmacologic therapy for dialysis hypotension is to reduce symptoms, improve quality of life, protect organ ischemia, and improve prognoses. |